ストックスクリーナーアプリを入手
36.56
0.54%
-0.20
アフターアワーズ：
36.56
前日終値:
$36.76
開ける：
$36.29
24時間の取引高:
1.33M
Relative Volume:
0.89
時価総額：
$6.78B
収益：
$29.52M
当期純損益:
$-567.06M
株価収益率:
-9.9891
EPS:
-3.66
ネットキャッシュフロー:
$-551.11M
1週間 パフォーマンス:
+0.25%
1か月 パフォーマンス:
-4.07%
6か月 パフォーマンス:
-23.43%
1年 パフォーマンス:
+4.70%
1日の値動き範囲:
$36.01
$37.89
1週間の範囲:
$35.40
$37.89
52週間の値動き範囲:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
名前
Revolution Medicines Inc
セクター
電話
415-766-3638
住所
700 SAGINAW DR, REDWOOD CITY, CA
RVMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
36.56 | 6.78B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-16 | 繰り返されました | Needham | Buy |
| 2024-07-12 | 開始されました | Barclays | Overweight |
| 2024-07-08 | 開始されました | Jefferies | Buy |
| 2024-04-12 | 繰り返されました | Needham | Buy |
| 2024-04-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 開始されました | Piper Sandler | Overweight |
| 2024-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-01-04 | 開始されました | Wedbush | Outperform |
| 2023-11-16 | 開始されました | Raymond James | Outperform |
| 2023-02-28 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-10-21 | 開始されました | Oppenheimer | Outperform |
| 2022-05-20 | 開始されました | BofA Securities | Neutral |
| 2022-03-01 | アップグレード | Stifel | Hold → Buy |
| 2021-09-23 | 開始されました | Stifel | Hold |
| 2021-08-12 | ダウングレード | Goldman | Buy → Neutral |
| 2021-05-18 | 開始されました | Goldman | Buy |
| 2020-05-21 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-09 | 開始されました | Cowen | Outperform |
| 2020-03-09 | 開始されました | Guggenheim | Buy |
| 2020-03-09 | 開始されました | JP Morgan | Neutral |
すべてを表示
Revolution Medicines Inc (RVMD) 最新ニュース
Revolution Medicines to Participate in April 2025 Investor Conferences - GlobeNewswire
Revolution Medicines at Stifel Forum: RAS-Driven Cancer Insights By Investing.com - Investing.com Canada
Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines stock hits 52-week low at $30.02 - Investing.com Australia
Revolution Medicines at Needham Conference: Progress in Cancer Treatment - Investing.com Australia
Revolution Medicines at Needham Conference: Progress in Cancer Treatment By Investing.com - Investing.com Canada
Revolution Medicines stock hits 52-week low at $30.02 By Investing.com - Investing.com India
When the Price of (RVMD) Talks, People Listen - news.stocktradersdaily.com
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Revolution Medicines to Deliver Multiple Presentations at - GlobeNewswire
Groundbreaking Lung Cancer Drug Data Revealed: Revolution Medicines' First Clinical Results - Stock Titan
Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now - MSN
Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums - Stock Titan
Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock By Investing.com - Investing.com South Africa
Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock - Investing.com
Revolution Medicines executive sells shares worth $128,598 By Investing.com - Investing.com Australia
Revolution Medicines’ general counsel sells $56,920 in stock By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark Goldsmith sells $458,255 in stock By Investing.com - Investing.com Australia
Revolution Medicines CFO Jack Anders sells $72,771 in stock By Investing.com - Investing.com Canada
Revolution Medicines’ general counsel sells $56,920 in stock - Investing.com India
Revolution Medicines CFO Jack Anders sells $72,771 in stock - Investing.com
Revolution Medicines Executives Sell Shares - TradingView
Revolution Medicines COO Margaret Horn sells $119,385 in stock - Investing.com
Revolution Medicines Inc (RVMD) Should Be Considered For The Next Few Weeks - Stocks Register
Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 20 - GuruFocus.com
Revolution Medicines at Leerink Conference: Expanding RAS Inhibitor Reach By Investing.com - Investing.com Canada
Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com Canada
Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa
(RVMD) Long Term Investment Analysis - news.stocktradersdaily.com
Revolution Medicines at Barclays Conference: Focus on Pancreatic Cancer Trials - Investing.com UK
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers - ACS Publications
Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs - TipRanks
HC Wainwright Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - Defense World
Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now - Yahoo Finance
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Revolution Medicines’ (RVMD) “Outperform” Rating Reiterated at Wedbush - Armenian Reporter
Long Term Trading Analysis for (RVMD) - Stock Traders Daily
Wedbush Reaffirms Outperform Rating for Revolution Medicines (NASDAQ:RVMD) - Defense World
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Revolution Medicines Inc (RVMD) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):